Observations on the Impact of COVID-19 Disease on Oncology Practice from CancerLinQ®:

Targeted Therapies Used in Lung Cancer

June 3, 2020

These reports on the impact of COVID-19 on the practice of oncology are drawn from de-identified CancerLinQ data, collected to support quality improvement at our subscribing practices. For more information, please see https://cancerling.org/covid-19. For feedback or questions, contact info@cancerling.org. This data is accurate as of 6/3/20, but there can be latency in reporting, and we will update it as new data becomes available.

Figure 1 shows the weekly number of patients with drug orders or administration events for targeted therapies used in lung cancer at the 35 organizations that provide daily or weekly incremental updates. Weeks 1 and 53 have fewer than 7 days, and the final entry (week 22) for 2020 is an incomplete week with only 3 days.
Figure 1: Number of patients with new prescription orders or administration events recorded in the EHRs of organizations for the specified drug by week for selected agents (blue = 2019, orange = 2020)